Aciclovir gel - Sakai/SkyePharma

Drug Profile

Aciclovir gel - Sakai/SkyePharma

Alternative Names: Acyclovir gel - Sakai/SkyePharma

Latest Information Update: 24 Apr 2007

Price : $50

At a glance

  • Originator Bioglan AB
  • Class Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Herpes simplex virus infections; Varicella zoster virus infections

Most Recent Events

  • 04 Nov 2002 Aciclovir gel is now being developed by SkyePharma
  • 31 May 2002 Bioglan's intellectual property rights to three topical drug delivery technologies, including ES-GEL™, have been acquired by SkyePharma
  • 18 Feb 2000 Preclinical development for Varicella zoster virus infections in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top